eXoZymes (NASDAQ:EXOZ) Insider Damien Alan Perriman Sells 3,729 Shares of Company Stock

eXoZymes Inc. (NASDAQ:EXOZ) insider Damien Alan Perriman sold 3,729 shares of the firm’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $5.21, for a total value of $19,428.09. Following the sale, the insider owned 28,692 shares of the company’s stock, valued at $149,485.32. This represents a 11.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

eXoZymes Stock Down 1.0%

Shares of NASDAQ:EXOZ traded down $0.04 during trading on Monday, hitting $3.96. The company’s stock had a trading volume of 16,572 shares, compared to its average volume of 6,871. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.81 and a current ratio of 3.81. eXoZymes Inc. has a fifty-two week low of $3.70 and a fifty-two week high of $18.40. The stock’s 50-day moving average price is $5.96 and its two-hundred day moving average price is $7.40. The company has a market capitalization of $36.83 million, a PE ratio of -3.33 and a beta of 3.19.

eXoZymes (NASDAQ:EXOZ) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.33) EPS for the quarter. As a group, sell-side analysts expect that eXoZymes Inc. will post -1.19 EPS for the current year.

Institutional Trading of eXoZymes

A hedge fund recently bought a new stake in eXoZymes stock. BlackRock Inc. bought a new stake in shares of eXoZymes Inc. (NASDAQ:EXOZ) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 9,610 shares of the company’s stock, valued at approximately $81,000. BlackRock Inc. owned about 0.10% of eXoZymes at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on EXOZ shares. Zacks Research upgraded eXoZymes to a “hold” rating in a research note on Friday, October 2nd. Weiss Ratings restated a “sell (e+)” rating on shares of eXoZymes in a research note on Wednesday, August 26th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

eXoZymes Company Profile

eXoZymes, Inc is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.